25+ years of progressive experience delivering regulatory excellence across medical devices, pharmaceuticals, and combination products
Senior regulatory affairs executive with proven expertise in leading global teams and navigating complex regulatory landscapes
Julia Ding is a seasoned regulatory affairs professional with over 25 years of progressive experience in the life sciences industry. Currently serving as a self-employed regulatory consultant since September 2024, she brings deep expertise from senior leadership roles at Fortune 500 companies including Thermo Fisher Scientific, BD, and Abbott.
Complex regulatory pathways for drug-device combinations
510(k) submissions, EUMDR compliance, global approvals
In vitro diagnostics, CLIA waiver experience
Regulatory transformation programs and process optimization
Managing 100+ professionals across international markets
Specialized regulatory guidance for innovative delivery platforms
Comprehensive regulatory affairs consulting tailored to your specific needs
Comprehensive regulatory pathway planning and strategic guidance for product approvals across global markets.
Expert preparation and management of FDA submissions, including 510(k) clearances and regulatory communications.
Specialized regulatory consulting for drug-device combinations and complex product classifications.
Regulatory team development, process optimization, and organizational transformation programs.
European regulatory compliance guidance and MDR transition support for medical device companies.
In vitro diagnostics regulatory strategy, CLIA waiver applications, and laboratory compliance guidance.
Progressive leadership roles at industry-leading organizations
Independent Practice
Providing strategic regulatory affairs consulting services to life sciences companies across medical devices, pharmaceuticals, and combination products.
Thermo Fisher Scientific
BD (Becton, Dickinson and Company)
Abbott Laboratories
ACON Biotech
Ready to discuss your regulatory affairs needs? Let's schedule a consultation.